L ysophospholipids are a diverse class of chemical transmitters that includes sphingosine 1-phosphate (S1P) 1 , lysophoshatidic acid (LPA) 2 , and more emerging bioactive lipids such as lysophosphatidylserine (lyso-PS) and lysophosphatidylinositol (lyso-PI) 3 . Lysophospholipids are generally thought to act through discrete sets of G-protein-coupled receptors (GPCRs) 4 , although other categories of receptors have also been described 5 . Diverse areas of biology are impacted by lysophospholipid signaling, leading to therapeutics such as S1P receptor modulators to treat multiple sclerosis and potentially other autoimmune disorders 6 .
scaffolds used to create irreversible inhibitors of other serine hydrolases, such as activated carbamates 20 and ureas 21 . We therefore sought to discover new types of ABHD12 inhibitors by high-throughput screening (HTS). Although an HTS-compatible assay for ABHD12 has been described that uses an arachidonoyl glycerol substrate 22 , we favored development of an assay based on a lysophospholipid substrate for the enzyme. Accordingly, we developed an enzymecoupled fluorescence assay that measures ABHD12-mediated hydrolysis of lysophosphatidic acid (lyso-PA) 23 (Fig. 1a,b and Supplementary Fig. 1 ), which we implemented in a 384-well format to screen the 16,000-compound Maybridge HitFinder library tested at 10 µ M. The HTS assay showed excellent statistics with average Zʹ and S/B values of 0.78 and 5.5, respectively, and identified ~ 200 compounds that displayed > 50% inhibition (1.2% hit rate; Fig. 1c and Supplementary Fig. 2 ). Two secondary screens were then used to remove false-positive compounds: (i) an LC-MS-based lyso-PS hydrolysis assay 15 and (ii) a competitive activity-based protein profiling (ABPP) assay using the serine hydrolase-directed fluorophosphonate-rhodamine (FP-Rh) probe 24 . Only one compound (#175) showed activity in both secondary assays ( Supplementary  Fig. 3 ). We found, through resynthesis, that the structure of this compound had been misassigned by the supplier as a semithiocarbazide ( Supplementary Fig. 4 ) and instead represented a thiourea that we refer to hereafter as DO130 (1 ; Fig. 1d and Supplementary  Fig. 4 ). DO130 inhibited the lyso-PS lipase activity of ABHD12 with an IC 50 value of 1.3 µ M ( Fig. 1e and Supplementary Fig. 5 ). In contrast, we prepared an authentic sample of the semithiocarbazide (termed DO127 (2 ) ) and found that it showed no activity against ABHD12 ( Supplementary Fig. 4 ). The HTS study is summarized in Supplementary Table 1 .
Optimization of thiourea ABHD12 inhibitors. For the purposes of optimizing thiourea inhibitors of ABHD12, we took advantage of a tailored, clickable activity-based probe targeting this enzyme, termed JJH350 (3 ; Supplementary Fig. 6 ), which originated from an N-hydroxyhydantoin (NHH) carbamate library of covalent serine hydrolase inhibitors 25 . Although we were unsuccessful in our efforts to create in vivo-active inhibitors of ABHD12 based on the NHH carbamate scaffold, JJH350 offered a more selective probe compared to FP-Rh for assessing ABHD12 activity in diverse biological systems (see below). Using JJH350 for competitive gelbased ABPP of ABHD12 in mouse brain membrane proteome, we measured an IC 50 value of 1.1 µ M for DO130 ( Supplementary  Fig. 7 and Supplementary Table 2 ), which is similar to the value measured with the lyso-PS lipase assay ( Fig. 1e ). A series of modifications to DO130, including conversion of the 3-chloro-5-trifluoromethyl group to a 4-trifluoromethoxyphenyloxy group (DO230 (4 )) and addition of Cl groups at the 3-position of the pyridine ring (DO253 (5 )) and 2-position of the phenyl ring, improved the potency of ABHD12 inhibition and culminated in compound DO264 (6 ) , which displayed an IC 50 value of 11 nM (9.6 nM-13 nM 95% confidence interval (CI)) ( Fig. 2a ; Supplementary Fig. 7 and Supplementary Table 2 ). Modifications to the thiourea group, on the other hand, decreased potency, with N-methylthiourea-(DO276 (7 ) ) and urea-(DO277 (8 )) analogs of DO264 displaying IC 50 values of 1.1 µ M and 170 nM, respectively (Supplementary Fig. 7 and Supplementary Table 2 ).
Competitive gel-and mass spectrometry (MS)-based ABPP with FP-Rh or a biotinylated FP probe 26 , respectively, revealed that DO264 and other (thio)urea analogs displayed excellent selectivity for ABHD12 compared to other mouse brain serine hydrolases ( Fig. 2b and Supplementary Fig. 8 ). Our structure-activity relationship (SAR) analysis of ABHD12 inhibitors also identified an inactive analog of DO264 with an (S)-3-aminopiperidine arrangement ((S)-DO271 (9 ); Fig. 2a,b ; Supplementary Fig. 7 and Supplementary  Table 2 ), which we surmised could serve as a useful control compound for biological studies.
We next confirmed that DO264, but not (S)-DO271, blocked lyso-PS hydrolysis activities of recombinant mouse and human ABHD12 in transfected HEK293T cell lysates (DO264 IC 50 values of ~ 30 and 90 nM against mouse and human ABHD12, respectively; Supplementary Fig. 9 ) and the ABHD12-dependent lyso-PS lipase activity of membrane lysates from mouse brain (IC 50 = 2.8 nM, 2.4 nM-3.3 nM 95% CI; Fig. 2c and Supplementary  Fig. 9 ) and human THP-1 cells (IC 50 = 8.6 nM, 6.3 nM-12 nM 95% CI; Fig. 2d and Supplementary Fig. 9 ). We are unsure why DO264 exhibits improved potency for endogenous versus recombinant forms of ABHD12, but the difference is unlikely related to greater quantity of recombinant enzyme in the substrate assays, as we observed a similar IC 50 value for DO264 when tested against different amounts of ABHD12-transfected cell lysates ( Supplementary Fig. 9 ).
Further studies revealed that DO264 did not show time-dependent inhibition of ABHD12, which contrasted with the profile observed for the covalent NHH inhibitor JJH350 ( Supplementary  Fig. 10 ). We also found that dilution of DO264-treated ABHD12transfected HEK293T lysates resulted in the recovery of ABHD12 activity ( Supplementary Fig. 10 ). Finally, an alkyne analog of DO264 (DO274 (10 )) was generated and found to retain potent ABHD12 inhibitory activity, but showed no evidence of covalent modification of ABHD12 ( Supplementary Fig. 11 ). Taken together, these results indicate that DO264 acts as a reversible inhibitor of ABHD12. We also attempted to assess whether DO264 acts as a competitive inhibitor. We first found that, among a panel of tested detergents, only Triton X-100 solubilized ABHD12 ( Supplementary Fig. 12 ). However, the Triton-solubilized enzyme lost virtually all lyso-PS lipase activity ( Supplementary Fig. 12 ). We therefore evaluated the potency of DO264 inhibition of unsolubilized mouse ABHD12 in the presence of increasing concentrations of lyso-PS substrate (12.5-200 µ M) and found that the IC 50 value of inhibition shifted substantially toward the right (~5 to 70 nM) with greater substrate concentration ( Supplementary Fig. 12 ). These data, along with the blockade of FP-Rh (and JJH350) labeling of ABHD12 by DO264, are consistent with this compound acting as a competitive inhibitor of ABHD12.
DO264 alters (lyso)-PS content of human macrophages.
We next tested whether DO264 inhibits ABHD12 in cells. As ABHD12 is highly expressed in macrophages and microglia 13, [27] [28] [29] , we first evaluated DO264 activity in the human monocytic THP-1 cell line. THP-1 cells were treated with DO264 for 4 h, lysed, and then analyzed by competitive gel-based ABPP with the JJH350 probe, which revealed concentration-dependent inhibition of ABHD12 with complete blockade observed at 1 µ M of DO264 ( Fig. 3a) . By contrast, ABHD12 activity was unaffected by (S)-DO271 (1 µ M) in THP-1 cells ( Fig. 3a ). Membrane lysates from DO264-treated cells also showed concentration-dependent reductions in lyso-PS hydrolysis activity, from which an in situ IC 50 value of 26 nM (20 nM-34 nM 95% CI) was determined ( Fig. 3b and Supplementary  Fig. 13 ) and found to match the in situ IC 50 value estimated by competitive ABPP ( Supplementary Fig. 13 ).
We next confirmed that DO264 inhibits ABHD12 with excellent selectivity in THP-1 cells. In brief, THP-1 cells labeled with isotopically heavy or light amino acids were treated with DMSO and compound (DO264 or (S)-DO271, 1 µ M), respectively, for 4 h and then lysed, reacted with FP-biotin, and processed for quantitative MS-based ABPP as previously described 21 . These experiments revealed that DO264 blocked > 95% of ABHD12 activity without affecting the activity of other serine hydrolases in THP-1 cells, whereas (S)-DO271 did not affect the activity of any serine hydrolases, including ABHD12 (Supplementary Fig. 14 and Supplementary Table 3 ).
DO264, but not (S)-DO271, produced substantial elevations in the lyso-PS content of THP-1 cells ( Fig. 3c ). Other measured (lyso)phospholipids were mostly unchanged in DO264-treated THP-1 cells ( Supplementary Table 4 ), with the exception of a concentration-dependent increase in several 20:4 PS lipids and a corresponding decrease in 18:1 PS lipids ( Fig. 3c and Supplementary  Fig. 14) . These data are consistent with previous findings in ABHD12 -/mice, which display elevations in both lyso-PS and 20:4 PS (and reductions in 18:1 PS) content in the CNS 15 . Similar lyso-PS and PS changes were observed in phorbol 12-myristate 13-acetate (PMA)-differentiated THP-1 cells ( Supplementary  Fig. 15 ), which adopt a more macrophage-like cell state compared to undifferentiated THP-1 cells. We also found that DO264 inhibits ABHD12 activity ( Supplementary Fig. 16 ) and alters lyso-PS and PS content in primary human macrophages, which showed elevations in both lyso-PS and 20:4 PS following 4 or 24 h treatment with DO264 (1 µ M), but not (S)-DO271 (1 µ M) ( Fig. 3d ; Supplementary Figs. 17 and 18 ).
Taken together, these data reveal that ABHD12 controls a dynamic pool of lyso-PS in human macrophages that undergoes substantial change following acute inactivation of the enzyme. The observation that alterations in 20:4 PS occur on a similar time scale following ABHD12 inhibition points to a rapid reacylation pathway for lyso-PS in macrophages, possibly mediated by a 20:4-preferring lysophospholipid acyltransferase 30 .
DO264 alters brain (lyso)-PS content in vivo. C57BL/6 mice treated with DO264 by intraperitoneal (i.p., 4 h or 24 h) or oral (p.o., 4 h) administration showed dose-dependent reductions in brain ABHD12 activity as measured by ex vivo analysis with the JJH350 probe, with complete inhibition being observed at the 30 and 60 mg/ kg doses (Fig. 4a,b and Supplementary Figs. 19 and 20) . By contrast, (S)-DO271 (60 mg/kg, 4 h) did not block brain ABHD12 activity in mice ( Fig. 4a,b ). The inhibition of ABHD12 activity was observed for 4-24 h post treatment with DO264 (30 mg/kg, i.p.), with partial recovery observed at 48 h post dosing ( Fig. 4c,d ). No changes in ABHD12 protein abundance, as measured by western blotting, were observed in DO264-treated animals ( Supplementary Fig. 19 ). ABPP studies confirmed that DO264 displayed excellent selectivity for ABHD12 in vivo ( Fig The result is a representative of two independent experiments. c,d, Concentration-dependent inhibition of lyso-PS hydrolysis activity in mouse brain (c) or THP-1 (d) membrane proteome (0.4 mg/mL) by DO264 as determined using 17:1 lyso-PS as a substrate. Data were normalized to ABHD12 -/brain and JJH350 (10 µ M)-treated THP-1 membrane proteomes, respectively, to designate the ABHD12-dependent component of lyso-PS hydrolysis in these proteomes (see Supplementary Fig. 9 ) and represent average values ± s.d. n = 4 and 3 independent experiments for c and d, respectively.
and Supplementary Table 3 ). Among the more than 65 other serine hydrolases quantified by MS-based ABPP, only ABHD2 and PLA2G6 showed partial (~40-50%) reductions in activity in DO264treated mice ( Fig. 4e and Supplementary Table 3 ); however, these changes may reflect an indirect outcome of ABHD12 inhibition, as DO264 did not inhibit mouse ABHD2 in vitro ( Supplementary  Fig. 8 ) or human ABHD2 in situ ( Fig. 3c ), nor did the compound inhibit recombinantly expressed PLA2G6 ( Supplementary Fig. 21 ). The MS-based ABPP results ( Fig. 4e and Supplementary Table 3 ), along with gel-based ABPP assays with recombinant enzymes ( Supplementary Fig. 21 ), also confirmed that the candidate lyso-PS biosynthetic enzymes ABHD16A and PS-PLA1 were not inhibited by DO264. We also determined, using general and tailored ABPP probes (FP-Rh and JJH350, respectively), that DO264, but not (S)-DO271 (i.p., 30 mg/kg, 4 h), selectively inhibited ABHD12 in peripheral tissues of mice ( Supplementary Fig. 22 ). We further found that JJH350 can function as an in vivo target engagement probe for ABHD12, as the sequential administration of DO264 (30 mg/kg, p.o., 4 h) followed by JJH350 (30 mg/kg, i.p., 4 h) confirmed inhibition of ABHD12 by DO264 in mouse brain and peripheral tissues ( Supplementary Fig. 23 ). Finally, we measured blood and brain concentrations of DO264 in mice, revealing good peripheral (~4-9 µ M in blood) and central (~3-6 µ M in brain) exposure of the compound at 4 h following i.p. or p.o. administration (30 mg/kg). (S)-DO271 showed lower exposure, but at 60 mg/kg (i.p.) approximated exposures observed with DO264 ( Supplementary Fig. 23 ).
DO264 (1-60 mg/kg, i.p., 24 h), but not (S)-DO271 (60 mg/kg, i.p., 24 h), dose-dependently increased most brain lyso-PS species, as well as select 20:4 PS species ( Fig. 4f and Supplementary Fig. 24 ). Maximal lyso-PS and 20:4 PS elevations were observed at 30 mg/kg of DO264, which matched the dose at which full ABHD12 inhibition was observed ( Fig. 4a and Supplementary Fig. 19 ). Time-course studies revealed that the lyso-PS changes caused by DO264 were detectable by 4 h and were maximal at 24 h post dosing ( Fig. 4g ), whereas PS changes accumulated more slowly ( Supplementary  Fig. 24 ). ABHD12 -/mice also showed elevations in 20:4 lyso-PI 15 , and an increase in this lipid was also observed in DO264-but not (S)-DO271-treated mice ( Supplementary Fig. 24 ). ABHD12 has been shown to hydrolyze the endocannabinoid 2-arachidonoylglycerol (2-AG) 31, 32 and, in certain cellular settings (for example, microglial cultures 29 ), can regulate 2-AG content. However, brain tissue from DO264-treated or ABHD12 -/mice did not show changes in 2-AG (Supplementary Table 4 ).
The elevations in brain lyso-PS and 20:4 PS in DO264-treated mice did not generally approach the magnitude of changes observed in ABHD12 -/mice ( Fig. 4f,g and Supplementary Fig. 24 ), suggesting that more chronic inhibition of ABHD12 might lead to further augmentation of brain (lyso)-PS content. To address this question, we first treated adult mice with DO264 or (S)-DO271 (30 mg/kg daily, p.o.) for two weeks and confirmed that neither compound produced overt signs of toxicity, such as weight loss ( Supplementary Fig. 25 ) or behavioral distress. We then proceeded Supplementary Table 4 . Supplementary Table 4 .
to treat 8-month-old mice with DO264, (S)-DO271 (30 mg/kg daily, p.o. for each), or vehicle for four weeks. Prior to sacrifice and lipid analysis, we tested the mice for auditory function and found that, unlike ABHD12 -/mice, which showed robust auditory defects as reported previously 15 (Fig. 5a ), the DO264-treated mice showed only a mild trend toward impairment at lower decibels that failed to reach statistical significance in comparison to either vehicle-or (S)-DO271-treated mice (Fig. 5b) . Substantial elevations in both lyso-PS and 20:4 PS occurred in brain tissue from the DO264-treated mice ( Fig. 5c and Supplementary Fig. 26 ), and these changes included species such as 18:0/20:4 and 20:0/20:4 PS that were unaltered in mice treated acutely with DO264 ( Supplementary Fig. 24 ). Nonetheless, even after 4 weeks of treatment with DO264, the elevations in many brain (lyso)-PS species remained less substantial than the changes observed in ABHD12 -/mice ( Fig. 5c and Supplementary Fig. 26 ). These data, taken together, indicate that both acute and chronic treatment with DO264 raise brain (lyso)-PS in vivo, but these changes are less dramatic than the (lyso)-PS changes observed in ABHD12 -/mice and do not result in substantial auditory dysfunction.
Heightened immune responses in ABHD12-disrupted mice.
Both ABHD12 and major lyso-PS receptors are strongly expressed in immune cells, and previous studies from our lab and others have pointed to an immunomodulatory function for the ABHD12lyso-PS pathway that may involve both innate 13, 15 and adaptive 9, 11, 12 immunological systems. Nonetheless, how ABHD12 specifically contributes to dynamic immune responses in vivo remains unknown. We set out to investigate this question using the LCMV clone 13 (Cl13) model of immune challenge, which produces a panimmune suppressive state that promotes T cell exhaustion and virus persistence 33 . Relief of immune suppression by blocking negative regulatory molecules like PD-1 or IL-10 results in hastened control of Cl13 infection, as well as concomitant immune pathology that can produce severe morbidity and lethality 34, 35 . We found that infection with a persistent dose of Cl13 caused a striking pathological response in ABHD12 -/mice, indicated by hunched posture, ruffled fur, labored breathing, and death in ~ 50% of the animals (Fig. 6a) , correlating with gross lung damage ( Supplementary Fig. 27 ), whereas Cl13-infected ABHD12 +/+ mice displayed much healthier cage behavior, with only ~ 10% succumbing to infection (Fig. 6a) . A similar heightened pathology was observed in mice treated with DO264 in comparison to (S)-DO271 (30 mg/kg of DO264 or (S)-DO271, daily, i.p; Fig. 6b ). Consistent with ABHD12 disruption leading to a reversal of the immune suppressive environment during Cl13 infection 36, 37 , we found that bronchoalveolar lavage fluid (BALF) from ABHD12 -/or DO264-treated mice showed increases in total protein ( Supplementary Fig. 28 ) and pro-inflammatory Supplementary Table 4 .
chemokines (Fig. 6c,d ) compared to their respective control groups.
To provide further evidence that DO264 produces immunostimulatory effects through inhibiting ABHD12, we tested the compound alongside (S)-DO271 (30 mg/kg, daily, i.p.) in ABHD12 -/mice and evaluated immunological parameters at day 10 post Cl13 infection. A similar fraction (~30-40%) of DO264-and (S)-DO271treated ABHD12 -/mice died before sacrifice at day 10, consistent with the response of ABHD12 -/mice to Cl13 infection in previous experiments (Fig. 6a) , and both groups of compound-treated animals also showed similar amounts of chemokines in BALF ( Supplementary Fig. 28 ). The DO264-treated ABHD12 -/mice paradoxically showed a reduction in BALF protein compared to (S)-DO271-treated ABHD12 -/mice ( Supplementary Fig. 28 ). We do not understand the basis for this difference, as it is opposite in directionality from the elevations in BALF protein observed for DO264 versus (S)-DO271 in ABHD12 +/+ mice ( Supplementary   Fig. 28 ). Regardless, our data indicate that DO264 treatment does not further exacerbate the heightened immunological responses observed in ABHD12 -/mice infected with Cl13, supporting the idea that this compound's immunostimulatory effects occur mainly through ABHD12 inhibition. The lung pathology caused by restoration of T cell function, for instance, by anti-PD-1 antibodies during persistent Cl13 infection depends on CD8 T cell-mediated killing 36, 37 . We found evidence for a similar mechanism of action in ABHD12 -/mice in which antiviral CD8 T cells from these animals displayed increased killing capacity compared to cells from ABHD12 +/+ mice in both spleen and lung ( Fig. 6e and Supplementary Fig. 29 ). Finally, ABHD12 -/mice that survived the initial exaggerated immune response (~days 8-15) displayed a gradual reduction in viral titers in the serum and lung over the ensuing weeks (Fig. 6f) . Taken together, these data indicate that the inactivation of ABHD12 promotes increased lung ) , regulated on activation, normal T cell expressed and secreted. e, ABHD12 -/mice kill adoptively transferred splenocytes displaying LCMV-specific antigen (GP33-41) more efficiently than ABHD12 +/+ mice. In vivo killing of immunogenic LCMV-specific GP33-41 peptide or unrelated NP118-126-peptide-pulsed target cells labeled with high or low CellTrace Violet (CTV), respectively, was measured in spleen and lung tissue from ABHD12 +/+ and ABHD12 -/mice 7 d post-infection with Cl13. See Supplementary Fig. 29 for diagram of FACS gating strategy. Data represent of mean values of two independent experiments of n = 5 mice per group ± s.e.m. Two-sided Student's t-test performed relative to ABHD12 +/+ mice). f, Cl13 viral titers were measured by plaque assay at the indicated days post-infection in either serum (left) or lung (right). Dotted lines indicate the limit of detection of the plaque assay. Two-sided Mann-Whitney U test was performed relative to ABHD12 +/+ data. pathology and leakage following Cl13 viral infection. The observed lung pathology also correlates with enhanced local chemokine production, T-cell mediated killing capacity, and, over time, superior control of viremia.
Discussion
Recent years have witnessed a massive gain in our understanding of the genetic basis of human neurological disorders, principally because of advances in DNA sequencing technologies 38 . Such studies illuminate gene products that play fundamental roles in the developing and adult nervous systems and have more recently pointed to a key contribution of the immune system to a range of neurological diseases 39, 40 . Nonetheless, the biochemical basis for many genetically defined neurological diseases remains unknown, and the causative mutations often occur in proteins of poorly characterized function. The development of selective chemical probes that can perturb CNS-disorder-related proteins acutely and reversibly in adult animals offers a compelling path to illuminate the functions of these proteins in physiology and disease.
We have described herein a versatile chemical tool set for the lysophospholipid hydrolase ABHD12, mutations in which cause the rare neurological disease PHARC 16, 17 , that includes a potent, selective, and in vivo-active inhibitor DO264, along with activitybased (JJH350) and inactive control ((S)-DO271) probes for biological studies. Using these chemical probes and ABHD12 -/mice 15 , we discovered concordant and discordant effects of genetic versus pharmacological inactivation of ABHD12 in vivo. Similar alterations in brain lyso-PS and PS content were, for instance, found in DO264-treated and ABHD12 -/mice, but PHARC-like auditory defects were primarily observed in the latter animals. We do not yet know whether this difference reflects the greater magnitude of change in brain (lyso)-PS in ABHD12 -/mice, which could in principle be due to submaximal inhibition of ABHD12 by DO264 in vivo, or whether these animals have a neurodevelopmental defect underlying their hearing dysfunction.
On the other hand, DO264-treated and ABHD12 -/mice exhibited similar phenotypic responses in the LCMV Cl13 model of immune challenge, pointing to an immunosuppressive function for ABHD12. Though the heightened immunological responses to LCMV Cl13 displayed by ABHD12-disrupted mice may reflect the direct action of lyso-PS lipids that accumulate in these animals, we note that our current mechanistic understanding of these immunological phenotypes is limited, and past studies have provided conflicting views on whether lyso-PS pathways suppress 11, 12 or promote 9 immune system function. Of course, the extent to which there is a functional connection between ABHD12 inactivation and individual lyso-PS lipids or specific lyso-PS receptors remains unknown, and we acknowledge the potential for several lyso-PS and 20:4 PS lipids, as well as other endogenous lysophospholipid substrates of ABHD12, such as lyso-PI lipids, which act on distinct receptors 41 , to contribute to phenotypes observed in DO264-treated and ABHD12 -/mice. We also call attention to potential signaling pathways for (lyso)-PS beyond GPCRs. Lyso-PS lipids have been found, for instance, to activate the TLR2 receptor 5 , which acts as a pattern recognition receptor in the innate immune system and is abundantly expressed in macrophages and microglia 42 . TLR2 agonists can induce microglia-mediated neurodegeneration both in primary neuronal cultures 43, 44 and in vivo 45 . Whether prolonged treatment with DO264, especially in older animals, leads to microgliosis, a phenotype observed in ABHD12 -/mice of 12-18 months 15 , is an important subject matter for future investigation. We also note that future pharmacological studies of ABHD12 in animal models would benefit from the development of additional inactive control compounds beyond (S)-DO271 that display more equivalent pharmacokinetics properties to DO264.
Finally, to what extent might our findings point to an immunological basis for PHARC? Hearing loss and motor dysfunction can be manifestations of autoinflammatory and autoimmune diseases 46, 47 , and some of these disorders are responsive to immunosuppressive therapy 6 . Our data suggest that evaluating such therapeutic agents in ABHD12 -/mice is warranted as a prelude to their potential assessment in PHARC subjects. Our findings also designate ABHD12 inhibitors as a novel strategy to promote immune function in vivo, which could have translational relevance for infectious disease and immuno-oncology.
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Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/ s41589-018-0155-8 mL heavy proteome were treated with 1 µ M FP-biotin separately for 30 min at room temperature, and the two solutions were combined for further MS sample preparation. The MS sample preparation was performed as described previously 13 . Peptides obtained from this procedure were acidified using formic acid (5% final concentration, v/v) and stored at -80 °C until MS analysis. MS run for proteomic samples was performed using a Orbitrap Velos mass spectrometer following previously described protocols 51, 52 . MS data analysis was performed as described prevously 13 . See Supplementary Table 3 for complete proteomic data and extracted serine hydrolase data.
Isolation and generation of primary human macrophages. All studies with samples from human volunteers followed the protocols approved by The Scripps Research Institute Institutional Review Board. Blood from healthy donors (females aged [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] were obtained after informed consent. Peripheral blood mononuclear cells (PBMCs) were purified over Lymphoprep gradients (Stem Cell Technologies, 07851) by layering 25 mL of blood onto 12.5 mL of Lymphoprep. Samples were fractionated by centrifugation at 750 × g for 20 min at room temperature with no brake. PBMCs were harvested from the interface and washed twice with DPBS. Contaminating red blood cells (RBCs) were lysed with 1X RBC Lysis Buffer (eBioscience, 00-4300-54) for 5 min at room temperature and washed twice with DPBS. PBMCs were plated in DPBS at a density of 2.26 × 10 5 cells/cm 2 and adherent monocytes attached after 1-2 h. Non-adherent cells were subsequently washed off the plates, and the culture media was added, which consisted of RPMI-1640 supplemented with 10% FBS, 10 mM HEPES, 1X GlutaMax (Life Technologies), 1 mM sodium pyruvate (Life Technologies), and 100 U/mL penicillin-streptomycin. Monocytes are differentiated with 50 ng/mL recombinant human M-CSF (Peprotech, 300-25) for 6 days with a media change on day 3. On day 6, the macrophages turn into differentiated resting macrophages. Gel-based competitive ABPP for in vivo inhibitor treatment. Tissues from mice treated with inhibitors were dounce homogenized in DPBS (1 mL for a half brain, spleen and liver, and 1.5 mL for lung) and then spun on a low-speed (1,400 × g for 3 min at 4 °C) to remove debris. For FP-Rh labeling, 2 μ L of 50 μ M FP-Rh was added to 50 μ L of the whole tissue lysate obtained above (2 μ M final) and incubated for 20 min at room temperature. For JJH350 labeling, 1 μ L of 500 μ M JJH350 was added to 50 μ L of the whole tissue lysate obtained above (10 μ M final) and incubated for 30 min at room temperature. 1.5 mL of cold DPBS was added to each probe-labeled sample and spun at 16,000 × g for 45 min at 4 °C. The resulting membrane pellet was resuspended in cold DPBS, and protein concentrations were adjusted to 1 mg/mL using the Bio-Rad DC protein assay kit. For FP-Rh labeled samples, the reactions were quenched by adding 20 µ L of 4X SDS-PAGE loading buffer, and the 30 μ L of the quenched samples were loaded on a gel for analysis. For JJH350-labeled samples, CuAAC reactions were performed as described above, and the reactions were quenched by adding 20 µ L of 4X SDS-PAGE loading buffer. The 40 μ L of the quenched samples were loaded on gel for analysis.
Measurement of drug concentration in brain and blood. Measurement of tissue drug concentration was performed at Pharmaron (Bejing, China). DO264 and (S)-DO271 were administered as described above and incubated for 4 h. The brain tissues were homogenized with 4× volume of water (mL) by brain weight (g). Blood was collected via cardiac puncture and immediately quenched with acetonitrile at 1:4 blood:acetonitrile ratio. The brain homogenate and blood samples from drug-treated mice were diluted by 1,000-to 2,000-fold with 50% ACN in H 2 O. 5 µ L of the diluted sample solutions were added to 50 µ L of the blank C57BL/6 J mice brain homogenate and blood, respectively, to make dose samples. To make calibration standards, the stock solutions of DO264 and (S)-DO271 (1 mg/mL in DMSO) were diluted with 50% ACN in H 2 O to generate serial concentrations of working solution. 5 µ L of the working solutions (5, 10, 20, 50, 100, 500, 1,000, 5,000 and 10,000 ng/mL) were added to 50 μ L of the blank C57BL/6 J mice blood to achieve calibration standards of 0.5-1,000 ng/mL (0.5, 1, 2, 5, 10, 50, 100, 500 and 1,000 ng/mL). 55 μ L of calibration standards and dose samples were added to 200 μ L of ACN to precipitate protein. Then, the samples were vortexed for 30 s. After centrifugation at 4 °C, 4,000 r.p.m. for 15 min, the supernatant was diluted five times with water. 5 µ L of the diluted supernatant was injected into the LC-MS/MS system for quantitative analysis (LCMS-8060, SHIMADZU).
Quantitative MS-ABPP sample preparation for mouse brain proteomes treated with DO264 in vitro and brain proteomes from mice treated with DO264 or (S)-DO271 in vivo. 1 mL of brain proteomes (2 mg/mL in DPBS) were labeled with 6 µ M FP-biotin for 1 h at room temperature, and the proteomes were denatured and precipitated using 4:1 MeOH/CHCl 3 (v/v). The precipitates were subject to reduction, alkylation, avidin-based enrichment, and on-bead trypsin digestion as described in ABPP-SILAC sample preparation. Following the on-bead trypsin digest, reductive dimethylation was performed as previously described 26, 53 .
